Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · IPCALAB

IPCA LAB LTD

HealthcarePharmaceuticals & Biotechnology₹47042 cr market cap
₹1860.50 ▲ +0.35% today As of 19 Nov 2026
52-week low ₹1302.0052-week high ₹2009.60

-7.7% from the 52-week high · +42.4% above the low

Ipca Laboratories Ltd. engages in the manufacture, research, and development of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 16,167 full-time employees. The firm is manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. The company offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The firm offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The products of the Company are sold in over 100 countries across the globe. The firm has 18 manufacturing units in India manufacturing API’s and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd and Tonira Exports Limited.

The short version. IPCA LAB LTD reported revenue of ₹2,910 crore for Sep 2026, up 13.8% from a year earlier. Net profit was ₹375 crore (up 32.5% year on year). Return on equity was 14.1% in Mar 2026. Promoter holding was 44.72% in Sep 2026, up 0.00 points over 8 quarters.

1 · The price

How has the stock traded?

IPCA LAB LTD trades 7.7% below its 52-week high and 42.4% above its 52-week low.

Change over period: —

1M+2.2%
3M-2.6%
6M+12.6%
1Y+30.3%

2 · The business

Is it growing?

Sales, year on year+13.8%

Sep 2026 revenue of ₹2,910 cr.

Profit, year on year+32.5%

Sep 2026 net profit of ₹375 cr.

Net margin12.9%

1.8 pts higher than a year earlier.

3-year growth34.3% profit

Revenue compounded at 15.5% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue29102788238823922556230922472245
Net profit37540229932628323368248
Net margin %12.914.412.513.611.110.13.011.1
EPS (₹)14.7915.8411.7912.8611.149.192.679.78

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue96468940770562445830542046493773
Net profit11417385474718841140606445
Net margin %11.88.37.17.515.221.013.011.8
EPS (₹)44.9829.0821.5718.5834.8544.9323.9917.6

3 · The quality

How well does it turn capital into profit?

Return on equity was 14.1% in Mar 2026; debt to equity is 0.09.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %14.110.68.68.1
Return on capital %16.413.011.211.6
EBITDA margin %21.017.917.116.5
Net margin %11.68.27.07.4

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR15.5%12.4%
Profit CAGR34.3%0.0%
Debt to equity0.09
Interest cover21.7x
Current ratio2.76
P/E ratio33.6

4 · The owners

Who holds it, and are they adding?

Promoter holding44.72%

Unchanged over 8 quarters.

Foreign institutions11.53%

Up 0.46 pts over 8 quarters.

Domestic institutions36.59%

Up 0.91 pts over 8 quarters.

Mutual fund schemes172

+47 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter44.7244.7244.7244.7244.7244.7244.7244.720.0
FII11.0710.7610.6710.4310.6310.6310.7311.53+0.46
DII35.6836.0636.236.7737.3237.4537.3736.59+0.91
Public8.538.468.418.077.337.27.187.15-1.38

Mutual fund holdings · Oct 2026

172 schemes hold this stock

125 the month before.

  • DSP Healthcare Fund7.49% of NAV
  • Baroda BNP Paribas Health and Wellness Fund6.06% of NAV
  • quant Healthcare Fund5.37% of NAV
  • TATA NIFTY MIDSMALL HEALTHCARE INDEX FUND4.04% of NAV
  • Motilal Oswal Nifty MidSmall Healthcare Index Fund4.03% of NAV
  • Kotak Mid Cap Fund3.68% of NAV
  • HDFC Mid Cap Fund3.47% of NAV
  • Mirae Asset Healthcare Fund3.33% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for IPCA LAB LTD are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about IPCA LAB LTD

What is the IPCA LAB LTD share price?

IPCA LAB LTD (IPCALAB) last closed at ₹1,860.50, up 0.35% on the day. Its 52-week range is ₹1,302.00 to ₹2,009.60.

What is the market cap of IPCA LAB LTD?

IPCA LAB LTD has a market capitalisation of about ₹47,042 crore. Its price-to-earnings ratio is 33.6.

How are IPCA LAB LTD's latest results?

IPCA LAB LTD reported revenue of ₹2,910 crore for Sep 2026, up 13.8% from a year earlier. Net profit was ₹375 crore (up 32.5% year on year). Return on equity was 14.1% in Mar 2026. Promoter holding was 44.72% in Sep 2026, up 0.00 points over 8 quarters.

Who owns IPCA LAB LTD?

As of Sep 2026, shareholding was: Promoter 44.72%, FII 11.53%, DII 36.59%, Public 7.15%.

How many mutual funds hold IPCA LAB LTD?

172 mutual fund schemes held IPCA LAB LTD in October 2026. That compares with 125 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 05 Aug 2025 · Final Dividend - Rs. 2
  • 27 Nov 2024 · Interim Dividend - Rs. 2
  • 06 Aug 2024 · Final Dividend - Rs. 2
  • 22 Nov 2023 · Interim Dividend - Rs. 2
  • 22 Nov 2022 · Interim Dividend - Rs. 4
  • 10 Jan 2022 · Stock Split From Rs.2/- to Rs.1/-

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.